All In Biotech

Drug Trial Radar · NCT07887984

Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma

Bispecific Antibody Therapy vs Autologous Stem Cell Transplantation as Consolidation for Newly Diagnosed, Standard Risk Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 920 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

920

Planned (sponsor's estimate)

Start

Dec 23, 2026

Primary completion

Aug 1, 2033

Study completion Aug 1, 2053

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II/III trial compares the usual treatment (daratumumab and hyaluronidase, lenalidomide, bortezomib and dexamethasone \[DaraRVd\] regimen followed by autologous stem cell transplant \[ASCT\] followed by maintenance therapy) to DaraRVd treatment followed by bispecific antibody therapy (teclistamab and/or talquetamab) followed by maintenance therapy in treating patients with newly diagnosed, standard risk multiple myeloma. Daratumumab is in a class of medications called monoclonal antibodies. Daratumumab and hyaluronidase works by helping the body to slow or stop the growth of cancer cells. Hyaluronidase is an endoglycosidase. It helps to keep daratumumab in the body longer so that the medication will have a greater effect. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Teclistamab and talquetamab are bispecific monoclonal antibodies that can bind to targets on both cancer cells and immune cells (T-cells) that may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving DaraRVd followed by teclistamab and/or talquetamab may work better in increasing the likelihood of reducing the cancer burden to the point that it is undetectable, and prolonging the time until the cancer returns compared to DaraRVd followed by ASCT.

Conditions

  • Multiple Myeloma (MM)

Interventions

  • Daratumumab and Recombinant Human HyaluronidaseDrug

    Given SC

  • LenalidomideDrug

    Given PO

  • BortezomibDrug

    Given SC

  • DexamethasoneDrug

    Given PO or IV

  • Autologous Hematopoietic Stem Cell TransplantationProcedure

    Undergo ASCT

  • MelphalanDrug

    Given IV

  • TeclistamabDrug

    Given SC

  • TalquetamabBiological

    Given SC

  • Positron Emission TomographyProcedure

    Undergo PET

  • Computed TomographyProcedure

    Undergo CT

  • Biospecimen CollectionProcedure

    Undergo collection of blood

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients who are classified as being MRD-negative post-consolidation (Phase II)Time frame: Up to 1 year from registration
  2. Progression-free survival (PFS) (Phase III)Time frame: From date of randomization to the date of documented disease progression and/or death due to any cause, whichever comes first, assessed up to 20 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.